Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

robot
Abstract generation in progress

ClaimsFiler is alerting investors of Soleno Therapeutics, Inc. (NasdaqCM: SLNO) who incurred losses exceeding $100,000 to file lead plaintiff applications by May 5, 2026. The class action lawsuit, pending in California, alleges that Soleno failed to disclose material information regarding potential safety concerns and commercial viability risks of its drug DCCR for Prader-Willi syndrome. Soleno and its executives are accused of minimizing evidence of excessive fluid retention in clinical trials, leading to undisclosed safety risks and lower commercial prospects for the drug.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin